Cancer treatment maker 2seventy bio said it will sell all its experimental cell therapies to Regeneron Pharmaceuticalso focus on its only approved product Abecma, sending 2seventy's shares up more than 14% in premarket trade.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,